BriaCell Therapeutics Corp. has reported its financial results for the third quarter and nine months ended April 30, 2026, revealing a net loss of $7.2 million for the quarter, compared to a loss of $6.2 million in the same period last year. For the nine-month period, the company recorded a net loss of $22.8 million, up from $18.4 million in the prior year. The increase in losses is attributed to higher operating expenses, particularly in research and development, which rose to $5.97 million for the quarter and $18.7 million for the nine months, reflecting ongoing clinical trials and expanded development activities.
Total operating expenses for the third quarter reached $7.6 million, an increase from $6.3 million in the previous year. The rise in expenses was driven by increased clinical trial costs, particularly for the pivotal Phase 3 study of Bria-IMT™, which accounted for $3.15 million in the quarter. General and administrative expenses also increased to $1.65 million, up from $1.52 million, primarily due to higher shareholder communication costs and share-based compensation.
BriaCell's total assets as of April 30, 2026, were reported at $27.1 million, a significant increase from $21.6 million at the end of the previous fiscal year. The company’s cash and cash equivalents decreased to $6.88 million from $10.49 million, while short-term investments rose to $15.92 million from $7.37 million. The company’s accumulated deficit has grown to $134.34 million, reflecting its ongoing investment in research and development.
Strategically, BriaCell has made significant advancements in its clinical programs, including the ongoing Phase 3 study of Bria-IMT™ for metastatic breast cancer, which is under Fast Track Designation by the FDA. The company has also expanded its pipeline with the development of Bria-OTS™ and Bria-OTS+™, personalized off-the-shelf immunotherapies. In February 2026, BriaCell entered into a purchase agreement with BriaPro Therapeutics Corp. to transfer its exclusive license for developing Soluble CD80, enhancing its focus on innovative cancer therapies.
Looking ahead, BriaCell plans to continue its focus on research and development while exploring additional sources of capital to support its operations. The company has raised approximately $30 million in gross proceeds from a public offering in January 2026 and is actively managing its working capital resources. However, the company acknowledges that its ability to continue as a going concern is contingent upon achieving profitable operations and securing necessary financing.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer, primarily metastatic breast cancer. Its lead product, Bria-IMT™, is a genetically engineered whole-cell immunotherapy designed to activate the immune system against tumors, often combined with immune checkpoint inhibitors. The company also develops personalized off-the-shelf immunotherapies for multiple cancers. BriaCell relies on third-party manufacturing and targets oncologists and cancer treatment centers globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.